Octreotide acetate combined with somatostatin upregulates miR-1291 and downregulates miR-331-3p in patients with cirrhosis and upper gastrointestinal bleeding.

Xiaodong Liu, Xiaohui Guo, Hu Zhou

Open access · greenAbstract read

In one paragraph

Article in American journal of translational research, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it

0cells of the map it votes in

1citing papers in PubMed

0.3field-weighted citation impact, top 40% of its field

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 2 citations in OpenAlex.

Effects of Vitamin C Combined with Growth Inhibitors on Gastrointestinal Bleeding in Cirrhosis.Contrast media & molecular imaging · 2022
Article

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 2 institutions in 1 country.

Xiaodong LiuDepartment of Gastroenterology, Affiliated Hospital of Hebei University of Engineering Handan 056002, Hebei, China.

Xiaohui GuoDepartment of Gastroenterology, Affiliated Hospital of Hebei University of Engineering Handan 056002, Hebei, China.

Hu ZhouDepartment of Function, HanDan Central Hospital Handan 056001, Hebei, China.

Hebei University of Engineering · CNHandan College · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveThis study aimed to explore the efficacy of octreotide acetate combined with somatostatin (OA + SS) for the treatment of patients with cirrhosis and upper gastrointestinal bleeding (UGIB).

methodsA total of 118 patients with cirrhosis and UGIB in our hospital were enrolled from June 2018 to September 2019. Fifty-seven were treated with OA alone (Group A) whereas 61 were treated with OA + SS (Group B).

resultsThe therapeutic effects, inflammatory cytokines, liver function indices, and relative expression levels of miR-1291 and miR-331-3p were then observed. Compared with the patients in Group A, those in Group B had lower post-treatment inflammatory cytokine levels (P < 0.05), better post-treatment liver function indices (P < 0.05), lower incidences of adverse reactions (P < 0.05), and a higher total effective rate (P < 0.05). The OA + SS treatment group had upregulated miR-1291 and downregulated miR-331-3p (P < 0.05).

conclusionOA + SS therapy is safe and effective for the treatment of patients with cirrhosis and UGIB.

Indexed as

miR-1291miR-331-3pOctreotide acetatepatients with cirrhosis with upper gastrointestinal bleedingsomatostatin

Identifiers

PMID34540125

PMCPMC8430138

OpenAlexW3200422441

What OpenQuestion holds

Textmetadata

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.